<DOC>
	<DOCNO>NCT03072992</DOCNO>
	<brief_summary>The aim study assess benefit treatment intravenous Curcumin® ( CUC-01 ) v placebo , combination paclitaxel chemotherapy , estimate risk adverse event patient locally advance metastatic breast cancer . This randomized , double-blind , placebo-controlled , two arm parallel group phase 2 clinical trial : Group A , 75 patient , treatment Curcumin ( CUC-01 , yellow solution ) , 300mg i.v . plus i.v . Paclitaxel ( colorless solution ) 80 mg /m2 BS i.e. , weekly 12 week . Group B , 75 patient , treatment Paclitaxel ( colorless solution ) 80 mg /m2 BS , i.v . plus placebo i.v . solution ( 250 ml , yellow solution masking/blinding ) , weekly 12 week . Primary objective study : To assess : - Efficacy combined therapy Curcumin ® , ( CUC-01 ) Paclitaxel v Paclitaxel patient advance metastatic breast cancer term Objective Response Rate ( ORR ) assess Modified Response Evaluation Criteria In Solid Tumours ( RECIST ) . Secondary objective study : To assess : - The safety Curcumin+Paclitaxel combination compare Paclitaxel+placebo treatment assessment adverse effect . - Quality life ( QOL ) patient treat Curcumin+Paclitaxel combination compare Paclitaxel+Placebo - Response duration term Progression free survival ( PFS ) , Time Disease Progression ( TTP ) Time treatment failure ( TTTF )</brief_summary>
	<brief_title>`` Curcumin '' Combination With Chemotherapy Advanced Breast Cancer</brief_title>
	<detailed_description>RATIONALE Various preclinical , clinical , animal study suggest curcumin potential antiproliferative , anti-invasive , antiangiogenic , mediator chemoresistance , chemopreventive , therapeutic agent . However , main problem associate use curcumin human low absorption gastrointestinal tract , poor solubility body fluid low bioavailability . To overcome pharmacokinetic bioavailability limitation oral administration , water soluble curcumin , Curcumin® ( CUC-01 ) injection , clear , yellow viscous solution intend dilution suitable parenteral fluid prior intravenous infusion elaborate . Curcumin® ( CUC-01 ) injection patent pharmacy product sell per individual prescription Germany country Cancer Centers . However , clinical efficacy safety formulation confirm study . Development multidrug resistance ( MDR ) variety conventional novel chemotherapeutic agent significant challenge effective cancer therapy . Paclitaxel , one prescribe conventional chemotherapeutic agent , act microtubule stabilizer block cancer cell G2/M phase , thus prevent mitosis . It also apoptosis inducer cancer cell . However , one main drawback use also substrate P-gp treatment PCL induce overexpression efflux pump cancer cell . NF-κB transcription factor control expression gene involve number physiological response include differentiation , inflammation , apoptosis upregulation P-gp . The PI3K/Akt pathway also another over-activated pathway wide range tumor type therefore over-activation lead increase cancer-cell survival , proliferation , growth also promote NF-κB activity , affect success chemotherapy Paclitaxel . Curcumin known downregulate PI3K/Akt NF-κB pathway independent , thus act mediator chemoresistance sensitize cancer cell conventional chemotherapeutic agent . It suggest co-administration Paclitaxel curcumin help overcome multidrug resistance cancer . Synergistic interaction curcumin paclitaxel demonstrate paclitaxel ( Taxol ) -resistant breast cancer cell , human breast cancer xenograft model , MDA-MB-231 MCF-7 human breast cancer cell many cancer cell line . In vivo , combination treatment produce three-fold tumor inhibition cell line . Furthermore , combination paclitaxel curcumin exert increased anti-tumor efficacy mouse model These result clearly indicate combination Curcumin paclitaxel could significant clinical advantage treatment breast cancer . Curcumin exert vitro anti-breast cancer activity regulation matrix metalloproteinase ( MMP ) -2 , B-cell lymphoma 2 ( Bcl-2 ) , Bax , flap endonuclease 1 ( Fen1 ) , NF-E2-related factor 2 ( Nrf-2 ) factor , phosphoinositide 3-kinase ( PI3K ) /protein kinase B ( Akt ) signal . Therefore , base evaluation , intend examine effect Curcumin ® , ( CUC-01 ) advance metastatic breast cancer randomize , double-blind , placebo-controlled study . STUDY DESIGN This randomize , double-blind , placebo-controlled , two arm parallel group phase 2 study : Group A , 75 patient , treatment Curcumin ( CUC-01 , yellow solution ) , 300mg i.v . plus i.v . Paclitaxel ( colorless solution ) 80 mg /m2 BS i.e. , weekly 12 week . Group B , 75 patient , treatment Paclitaxel ( colorless solution ) 80 mg /m2 BS , i.v . plus placebo i.v . solution ( 250 ml , yellow solution masking/blinding ) , weekly 12 week . Therapy schedule weekly : - Preload-infusion contain Dexamethasone 8 mg 100ml NaCl - Paclitaxel 80mg/m2 body surface 250 ml 0.9 % NaCl - Curcumin 300 mg placebo 250ml 0.9 % NaCl PRIMARY OBJECTIVE To assess : - Efficacy combined therapy Curcumin ® , ( CUC-01 ) Paclitaxel v Paclitaxel patient advance metastatic breast cancer term Objective Response Rate ( ORR ) SECONDARY OBJECTIVES To assess : - The safety Curcumin+Paclitaxel combination compare Paclitaxel+placebo treatment assessment adverse effect . - Quality life ( QOL ) patient treat Curcumin+Paclitaxel combination compare Paclitaxel+Placebo - Response duration term Progression free survival ( PFS ) , Time Disease Progression ( TTP ) Time treatment failure ( TTTF ) NUMBER OF SUBJECTS 150 TEST PRODUCT , DOSE , AND ROUTE OF ADMINISTRATION Curcumin® ( CUC-01 ) injection , BRIU GmbH dose 300 mg. Each vial contain 20 ml concentrate ( concentration Curcumin - 15 mg/ml ) contain total 300 mg Curcumin , dilute 250 ml physiological solution ( 0.9 % NaCl ) use , total volume - 270 ml infusion solution . Investigational Active Ingredients : Curcuminoids ( syn : Curcumin , isolate turmeric rhizome Curcuma longa , Zingiberaceae . CUC-01 administer intravenously ( IV ) every 7 day 12 week . Therapy schedule weekly : - Preload-infusion contain Dexamethasone 8 mg 100ml NaCl - Curcumin 300 mg 250ml 0.9 % NaCl - Paclitaxel 80mg/m2 body surface 250 ml o.9 % NaCl CONTROL PRODUCT , DOSE AND ROUTE OF ADMINISTRATION Placebo : Riboflavin solution strong yellow-orange color visually distinguishable Curcumin . Placebo administer intravenously ( IV ) every 7 day 12 week Therapy schedule weekly : - Preload-infusion contain Dexamethasone 8 mg 100ml NaCl - Placebo ( Riboflavin solution ) 250ml 0,9 % NaCl - Paclitaxel 80mg/m2 body surface 250 ml 0.9 % NaCl EFFICACY EVALUATIONS . Primary endpoint Primary outcome measure : Clinically , radiologically measurable disease , tumour marker : - Objective response rate , assess Modified Response Evaluation Criteria In Solid Tumours ( RECIST ) use plain radiograph , ultrasound imaging , compute tomography scan magnetic resonance imaging . Other study may acceptable approval principal investigator . - Carcinoembryonic antigen ( CEA ) assay Cancer antigen15-3 ( CA 15-3 ) assay Secondary endpoint . Secondary outcome measure : - Adverse event define National Cancer Institute ( NCI ) Common Toxicity Criteria Version 4.0 ( CTCAE , v4.0≤ ) - Quality Life measure ( EORTC QLQ-C30 , Global Health Status/QoL scale ) Response Duration measure : - Progression free survival ( PFS ) assess study enrolment tumour progression per Modified RECIST criterion disease relate - Time Treatment Failure ( TTTF ) , assess study enrolment cessation study treatment reason - Time Tumour Progression ( TTP ) , assess study enrolment tumour progression per Modified RECIST criterion . Safety Evaluations Tolerability assess nature incidence adverse event . Change clinical safety lab baseline end study Incidence adverse event , ( CTCAE , v4.0≤ ) . STATISTICS Statistical analysis perform intent-to-treat basis . Survival Analysis time-to event endpoint . Assessment baseline characteristic - group comparison make : - Kruskal-Wallis ( KW ) non-parametric one way ANOVA rank order test , post hoc Dunn 's Multiple Comparison Test - parametric One-way independent measure ANOVA Dunnett 's Multiple Comparison Test , Analysis change within treatment group course study ( versus ) perform : - pair t-test ( parametric data - variable normal distribution ) or/and - Wilcoxon sign rink test ( nonparametric data ) , - Friedman test repeat several measure ( nonparametric data ) , Assessment efficacy study medication achieve group comparison mean change baseline ( difference treatment every single patient ) use : - Kruskal-Wallis ( KW ) non-parametric one way ANOVA rank order test , post hoc Dunn 's Multiple Comparison Test , and/or - parametric One-way independent measure ANOVA Tukkey 's Multiple Comparison Test ( variable normal distribution ) . Survival Analysis Statistical tool ( Kaplan-Mayer analysis log-rank test , Cox regression etc . ) use assessment TTP , PFS TTTF .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must fulfill follow criterion eligible study . Patient able give fully inform write consent accord International Conference Harmonisation ( ICH ) /Good Clinical Practice ( GCP ) guideline comply instruction protocol . Patients diagnose histologicallyproven breast carcinoma . Female subject 18 year old . Radiographic evidence measurable disease require must perform within 8 week prior randomization . Acceptable study include plain radiograph , ultrasound imaging , compute tomography scan magnetic resonance imaging . Other study may acceptable approval principal investigator . Bidimensionally measurable manifestation progressive advanced disease one prior chemotherapy regimen , locally advanced MBC progress within 12 month complete adjuvant neoadjuvant chemotherapy regimen case breast cancer weekly paclitaxel treatment consider adequate approach . No Herceptin treatment 4 week study . No chemotherapy bisphosphonate therapy 4 week random assignment study . Prior concomitant hormonal therapy allow . Karnofsky performance score ( KPS ) ≥60 , ECOG≤2 . Life expectancy 3 month great , estimate responsible clinician . Women childbearing age must use effective contraception . Sufficient hematological status . Adequate bone marrow function define : WBC great 4.0 x 10^9/L Granulocyte count great 1.5 x 10^9/L Platelet count great 100 x 10^9/L Haemoglobin great 10 g/dl ; Adequate renal function : calculated creatinine clearance ( CockcroftGault formula ) great 45 ml/min ; Adequate hepatic function define total bilirubin less Upper Limit Normal ( ULN ) , Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) less 2.5 x ULN , 1.5 x ULN Alkaline Phosphatase ( Alk Phos ) less 2.5 x ULN . Alk Phos le 5 x ULN unless patient bone metastasis ; EXCLUSION CRITERIA : inadequate renal hepatic function ; inadequate haematological status ; uncontrolled central nervous system metastasis ; severe cardiovascular disorder ; active infection ; Psychiatric addictive disorder condition , opinion investigator , would preclude patient meeting study requirement ; Other nonmalignant systemic and/or disease , would preclude patient receive study treatment would prevent require followup ( discretion principal investigator ) ; Known hypersensitivity study drug excipients ; Pregnancy lactation ; Second primary malignancy diagnose within last 5 year ( except adequately treat nonmelanoma skin cancer insitu cervical carcinoma adequately treat cone excision ) ; Herceptin and/or chemotherapy and/or bisphosphonate therapy le 4 week randomisation ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>